Influenza vaccine - Jiangsu Jindike Biotechnology

Drug Profile

Influenza vaccine - Jiangsu Jindike Biotechnology

Latest Information Update: 22 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jiangsu Jindike Biotechnology
  • Developer Jiangsu Jindike Biotechnology; Jiangsu Provincial Center for Disease Control and Prevention
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Influenza virus infections

Most Recent Events

  • 01 Aug 2016 Jiangsu Province Centers for Disease Control and Prevention completes a phase III clinical trial in Influenza virus infections (Prevention, In volunteers, In adolescents, In children, In adults) in China (IM) (NCT02710409)
  • 01 Jan 2016 Phase-III clinical trials in Influenza virus infections (Prevention, In volunteers, In adolescents, In children, In adults) in China (IM) (NCT02710409)
  • 01 May 2015 Phase-I clinical trials in Influenza virus infections (Prevention) in China (Parenteral) (NCT02269007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top